11248656

Pharmaceutical Spending Continues Steady Increase
“For the fourth straight year, prescription drug spending rose more than 17 percent in 2001, driven in large measure by a few heavily advertised, high-priced medications, a nonpartisan study released yesterday found.”

11222418

If Bioinformatics Is On the Ropes, Why Is UCSC’s David Haussler Smiling?
“I’m excited about the bioinformatics from the commercial point of view…”

11217023

Bioscience Booming
“Spending in Connecticut’s bioscience sector grew 18 percent in 2001, bucking a recession and infusing the state’s economy with $560 million more than it did the previous year, a new report shows.”

11212617

Unlocking the value in Big Pharma
“Although no guarantee of success, size is becoming more and more beneficial in several areas, including the costly process of discovering drugs.”

11210364

Putting the Tech in Biotech
“We are going through a massive, massive process of amalgamation, moving from the individual discovery into the data management mode,” explains Dr Bruce Cornell, Chief Scientist, at ASX listed biotech device manufacturer Ambri.

11175682

PPL to sell stem cell stake
“While historically we were spreading our resources across early-stage research, we’re now fairly and squarely behind our late-stage protein work.”

11143582

Do gene patents wrap research in red tape?
“Taking a position that seems to question biotech’s financial underpinnings, Affymetrix Corp. last week told a government panel that gene patents are hindering medical progress and that the United States should quit handing them out.”

11140362

Father of the Impossible Children
“Ignoring nearly universal opprobrium, Severino Antinori presses ahead with plans to clone a human being.”

11135101

Lucrative licensing deals with drug, biotech firms are raising ethics issues for hospitals
“A decade ago, many academic medical centers shunned profit-making deals with industry. But Harvard Medical School’s major teaching hospitals, hoping to replicate deals like Enbrel, are aggressively licensing discoveries by their physicians and researchers to biotechnology and pharmaceutical companies. And they are grappling with a host of business and ethics issues, including how to protect patients when hospitals and doctors have a financial stake in the outcome of their treatment.”

11105967

For Md. Biotechs, a Culture of Competition
“Biotechnology is becoming one of the hottest sectors among economic-development officials charged with generating new business growth. In the past, they tried to lure auto-manufacturing plants, customer call centers and most recently dot-com firms before the high-tech bubble burst. With demand growing for new medicines among an aging and increasingly affluent population, many states now see biotechnology as the surest ticket to prosperity.”